<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="85855">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02131350</url>
  </required_header>
  <id_info>
    <org_study_id>2617</org_study_id>
    <nct_id>NCT02131350</nct_id>
  </id_info>
  <brief_title>Combination Treatment of Intravitreal Ranibizumab, Focal/Grid Laser and Panretinal Photocoagulation in Patients With Diabetic Macula Edema</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shinshu University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shinshu University</source>
  <oversight_info>
    <authority>Japan: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the mean gain in best corrected visual acuity and
      the number of intravitreal ranibizumab (IVR) injections under the combination treatment of
      IVR, focal/grid laser and panretinal photocoagulation. Our hypothesis is that  suitable
      photocoagulation decreases the number of IVR injections.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2014</start_date>
  <primary_completion_date type="Anticipated">March 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>best corrected visual acuity</measure>
    <time_frame>every month, up to 36 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Best corrected visual acuity is measured with Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity chart and analysed.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Diabetic Macula Edema</condition>
  <arm_group>
    <arm_group_label>Ranibizumab with Photocoagulation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Photocoagulation</intervention_name>
    <description>Photocoagulation include focal/grid laser and/or panretinal photocoagulation</description>
    <arm_group_label>Ranibizumab with Photocoagulation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ranibizumab</intervention_name>
    <arm_group_label>Ranibizumab with Photocoagulation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  stable medication for the management  of diabetes within 3 months

          -  visual impairment due to focal or diffuse diabetic macula edema

          -  decreased vision due to diabetic macula edema  and not other causes

        Exclusion Criteria:

          -  concomitant conditions in the study eye that could prevent the improvement in VA on
             the study

          -  active intraocular inflammation or infection in either eye

          -  uncontrolled glaucoma in either eye

          -  treatment with antiangiogenic drugs in the study eye within 3 months

          -  history of stroke and uncontrolled hypertension
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Toshinori Murata</last_name>
    <phone>+81-263-37-2664</phone>
    <email>murata@shinshu-u.ac.jp</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department ou Ophthalmology Shinshu University School of Medicine</name>
      <address>
        <city>Matsumoto</city>
        <state>Nagano</state>
        <zip>3908621</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Takao Hirano</last_name>
      <phone>+81-263-37-2664</phone>
      <email>ieganka@shinshu-u.ac.jp</email>
    </contact>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 2, 2014</lastchanged_date>
  <firstreceived_date>April 22, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shinshu University</investigator_affiliation>
    <investigator_full_name>Takao Hirano</investigator_full_name>
    <investigator_title>Department of Ophthalmology Shinshu University School of Medicine</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Edema</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
